Lurbinectedin sensitizes PD-L1 blockade therapy by activating STING-IFN signaling in small-cell lung cancer.
Chakraborty S, Sen U, Ventura K, Jethalia V, Coleman C, Sridhar S, Banerjee A, Ozakinci H, Mahendravarman Y, Snioch K, de Stanchina E, Shields MD, Tomalin LE, Demircioglu D, Boyle TA, Tocheva A, Hasson D, Sen T.
Chakraborty S, et al. Among authors: banerjee a.
Cell Rep Med. 2024 Dec 4:101852. doi: 10.1016/j.xcrm.2024.101852. Online ahead of print.
Cell Rep Med. 2024.
PMID: 39657664
Free article.